Ask AI
BRCA Testing and Targeting in EBC

CE / CME

Germline BRCA Testing and Targeting in HER2-Negative Early-Stage Breast Cancer

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: May 07, 2024

Expiration: May 06, 2025

Activity

Progress
1
Course Completed

Introduction

In this case-based module, Tanya Gupta, MD, reviews important data informing the use of adjuvant PARP inhibition in patients with high-risk HER2-negative early-stage breast cancer (EBC) harboring germline BRCA mutations, along with how to identify eligible patients and perform genetic testing. 

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary. 

Clinical Care Options plans to measure the educational impact of this activity. Two questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared. 

Before continuing with this educational activity, please take a moment to answer the following questions. 

For those providing patient care, how many patients with breast cancer do you provide care for in a typical month?

In addition to ovarian suppression and the aromatase inhibitor, which of the following adjuvant therapy options would you recommend for this patient?

Which of the following management strategies would you recommend for this patient with grade 4 neutropenia?